ASH 2018 – CLL

The Bruton’s tyrosine kinase inhibitor acalabrutinib shows promise as a tolerable, effective monotherapy option for patients with previously untreated chronic lymphocytic leukemia. Read More ›

In evaluating the combination regimen of obinutuzumab, ibrutinib, and venetoclax as a potential limited-duration option in chronic lymphocytic leukemia (CLL), researchers reported a high mid-therapy response rate of relapsed/refractory patients with promising rates of minimal residual disease–negativity. Read More ›

The ALLIANCE study showed that ibrutinib produces superior progression-free survival to standard chemoimmunotherapy in older patients with chronic lymphocytic leukemia (CLL). Read More ›

The combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab achieved a high rate of undetectable minimal residual disease in previously untreated patients with IGHV-mutated chronic lymphocytic leukemia (CLL). Read More ›

An interim analysis from the informCLL Real-World Registry found that most ibrutinib-treated patients started at the FDA-recommended once-daily dose of 420 mg, with few dose interruptions or reductions over time. Read More ›

The combination of ibrutinib and CTL119, an anti-CD19 CAR T-cell antibody, showed promising results in a pilot trial with ibrutinib, with a high rate of patients achieving minimal residual disease–negative status. Read More ›

Researchers report promising findings for patients treated with a venetoclax-rituximab combination regimen in relapsed/refractory chronic lymphocytic leukemia (CLL). Read More ›

New data suggest that adding obinutuzumab to ibrutinib in patients with chronic lymphocytic leukemia (CLL) may be effective at improving minimal residual disease (MRD) response rates, especially in patients with low tumor burden after prior ibrutinib therapy. Read More ›